



BRIAN SANDOVAL
Governor

STATE OF NEVADA
DEPARTMENT OF HEALTH AND HUMAN SERVICES
DIVISION OF HEALTH CARE FINANCING AND POLICY
1100 E. William Street, Suite 101
Carson City, Nevada 89701
<http://dhcfp.nv.gov>

RICHARD WHITLEY
Director

LAURIE SQUARTSOFF
Administrator

NOTICE OF OPEN PUBLIC MEETING

The Division of Health Care Financing and Policy (DHCFP) Pharmacy and Therapeutics Committee will conduct a public meeting on **September 24, 2015**, beginning at **1:00 p.m.** at the following location:

**JW Marriott – Las Vegas
Marbella Room
221 N Rampart Blvd
Las Vegas, NV 89145
702-869-7777**

This meeting will be held only in Las Vegas, NV, there will be no teleconference to Carson City, NV.

Reasonable efforts will be made to assist and accommodate physically challenged persons desiring to attend the meeting. Please call Tanya Benitez at: 775-684-3722 or email Tanya.Benitez@dhcfp.nv.gov in advance, but no later than two working days prior to the meeting, so that arrangements may be conveniently made.

Items may be taken out of order.

Items may be combined for consideration by the public body.

Items may be pulled or removed from the agenda at any time.

Public comment is limited to 5 minutes per individual, organization, or agency, but may be extended at the discretion of the Chairperson.

AGENDA

- I. CALL TO ORDER AND ROLL CALL
- II. PUBLIC COMMENT

No action may be taken on a matter raised under this item of the agenda until the matter itself has been specifically included on the agenda as an item upon which action can be taken.

- III. **FOR POSSIBLE ACTION:** Review and Approval of the March 26, 2015 Meeting Minutes

IV. STATUS UPDATE BY DHCFP

- A. Public Comment
- B. Program Updates
 - 1. Agents used to treat opioid overdose

V. ANNUAL REVIEW - NEW DRUG CLASSES

A. ANTI-EMETIC – MISCELLANEOUS

- 1. Public Comment
- 2. Drug Class Review Presentation – Catamaran
- 3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
- 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Catamaran and the Division of Health Care Financing and Policy
- 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

B. PSYCHOSTIMULANTS - NARCOLEPSY AGENTS

- 1. Public Comment
- 2. Drug Class Review Presentation – Catamaran
- 3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
- 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Catamaran and the Division of Health Care Financing and Policy
- 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

C. LONG-ACTING ABUSE DETERRENT OPIOIDS

- 1. Public Comment
- 2. Drug Class Review Presentation – Catamaran
- 3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
- 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Catamaran and the Division of Health Care Financing and Policy
- 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

D. ANTILIPEMICS – OMEGA-3 FATTY ACIDS

1. Public Comment
2. Drug Class Review Presentation – Catamaran
3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Catamaran and the Division of Health Care Financing and Policy
5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

E. RESPIRATORY LONG-ACTING BETA AGONISTS/LONG-ACTING ANTIMUSCARINIC COMBINATIONS

1. Public Comment
2. Drug Class Review Presentation – Catamaran
3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Catamaran and the Division of Health Care Financing and Policy
5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

VI. ANNUAL REVIEW - ESTABLISHED DRUG CLASSES

A. NEUROPATHIC PAIN AGENTS

1. Public Comment
2. Drug Class Review Presentation – Catamaran
3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Catamaran and the Division of Health Care Financing and Policy
5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

B. FIBROMYALGIA AGENTS

1. Public Comment
2. Drug Class Review Presentation – Catamaran
3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups

4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Catamaran and the Division of Health Care Financing and Policy
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- C. OPIATE AGONISTS
1. Public Comment
 2. Drug Class Review Presentation – Catamaran
 3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Catamaran and the Division of Health Care Financing and Policy
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- D. MULTIPLE SCLEROSIS AGENTS - INJECTABLE
1. Public Comment
 2. Drug Class Review Presentation – Catamaran
 3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Catamaran and the Division of Health Care Financing and Policy
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- E. MULTIPLE SCLEROSIS AGENTS - ORAL
1. Public Comment
 2. Drug Class Review Presentation – Catamaran
 3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Catamaran and the Division of Health Care Financing and Policy
 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- F. VASODILATORS – ORAL
1. Public Comment
 2. Drug Class Review Presentation – Catamaran
 3. **For Possible Action:** Committee Discussion and Action

- a) Approve Clinical/Therapeutic Equivalency of Agents in Class
- b) Identify Exclusions/Exceptions for Certain Patient Groups
- 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Catamaran and the Division of Health Care Financing and Policy
- 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

G. PHOSPHATE BINDING AGENTS

- 1. Public Comment
- 2. Drug Class Review Presentation – Catamaran
- 3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
- 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Catamaran and the Division of Health Care Financing and Policy
- 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

H. INCRETIN MIMETICS

- 1. Public Comment
- 2. Drug Class Review Presentation – Catamaran
- 3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
- 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Catamaran and the Division of Health Care Financing and Policy
- 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

I. SODIUM-GLUCOSE CO-TRANSPORTER 2 (SGLT2) INHIBITORS

- 1. Public Comment
- 2. Drug Class Review Presentation – Catamaran
- 3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
- 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Catamaran and the Division of Health Care Financing and Policy
- 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

J. ANTI-MIGRAINE AGENTS - SEROTONIN-RECEPTOR AGONISTS

- 1. Public Comment

2. Drug Class Review Presentation – Catamaran
3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Catamaran and the Division of Health Care Financing and Policy
5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

K. ADHD AGENTS

1. Public Comment
2. Drug Class Review Presentation – Catamaran
3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Catamaran and the Division of Health Care Financing and Policy
5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

L. RESPIRATORY CORTICOSTEROIDS

1. Public Comment
2. Drug Class Review Presentation – Catamaran
3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Catamaran and the Division of Health Care Financing and Policy
5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

M. SUBSTANCE ABUSE AGENTS - MIXED OPIATE AGONISTS/ANTAGONISTS

1. Public Comment
2. Drug Class Review Presentation – Catamaran
3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Catamaran and the Division of Health Care Financing and Policy
5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

VII. ANNUAL REVIEW - ESTABLISHED DRUG CLASSES BEING REVIEWED DUE TO THE RELEASE OF NEW DRUGS.

A. ANTICOAGULANTS - ORAL

1. Public Comment
2. Drug Class Review Presentation – Catamaran
3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Catamaran and the Division of Health Care Financing and Policy
5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

B. INSULINS (VIALS AND PENS)

1. Public Comment
2. Drug Class Review Presentation – Catamaran
3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Catamaran and the Division of Health Care Financing and Policy
5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

C. ANXIOLYTICS, SEDATIVES, AND HYPNOTICS

1. Public Comment
2. Drug Class Review Presentation – Catamaran
3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Catamaran and the Division of Health Care Financing and Policy
5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

D. BETA-BLOCKERS

1. Public Comment
2. Drug Class Review Presentation – Catamaran
3. **For Possible Action:** Committee Discussion and Action

- a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
 - 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Catamaran and the Division of Health Care Financing and Policy
 - 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- E. TOPICAL ANTIFUNGALS (ONYCHOMYCOSIS)
 - 1. Public Comment
 - 2. Drug Class Review Presentation – Catamaran
 - 3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
 - 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Catamaran and the Division of Health Care Financing and Policy
 - 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- F. ANTICONVULSANTS
 - 1. Public Comment
 - 2. Drug Class Review Presentation – Catamaran
 - 3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
 - 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Catamaran and the Division of Health Care Financing and Policy
 - 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- G. ANDROGENS
 - 1. Public Comment
 - 2. Drug Class Review Presentation – Catamaran
 - 3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
 - 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Catamaran and the Division of Health Care Financing and Policy
 - 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- H. DISEASE-MODIFYING ANTIRHEUMATIC AGENTS
 - 1. Public Comment

2. Drug Class Review Presentation – Catamaran
3. **For Possible Action:** Committee Discussion and Action
 - a) Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b) Identify Exclusions/Exceptions for Certain Patient Groups
4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Catamaran and the Division of Health Care Financing and Policy
5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

VIII. ANNUAL REVIEW – DRUG CLASSES WITHOUT PROPOSED CHANGES

- A. TRAMADOL AND RELATED DRUGS
- B. NON-SEDATING H1 BLOCKERS
- C. INHALED AMINOGLYCOSIDES
- D. ANTIVIRALS - ALPHA INTERFERONS
- E. ANTI-HEPATITIS AGENTS – POLYMERASE INHIBITORS/COMBINATION PRODUCTS
- F. ANTI-HEPATITIS AGENTS – PROTEASE INHIBITORS
- G. ANTI-HEPATITIS AGENTS – RIBAVIRINS
- H. ANTI-HERPETIC AGENTS
- I. INFLUENZA AGENTS
- J. SECOND-GENERATION CEPHALOSPORINS
- K. THIRD-GENERATION CEPHALOSPORINS
- L. MACROLIDES
- M. QUINOLONES - 2ND GENERATION
- N. QUINOLONES - 3RD GENERATION
- O. SELF-INJECTABLE EPINEPHRINE
- P. MULTIPLE SCLEROSIS AGENTS - SPECIFIC SYMPTOMATIC TREATMENT
- Q. ANGIOTENSIN II RECEPTOR ANTAGONISTS
- R. ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)
- S. CALCIUM-CHANNEL BLOCKERS
- T. DIRECT RENIN INHIBITORS
- U. VASODILATORS – INHALED
- V. BILE ACID SEQUESTRANTS
- W. CHOLESTEROL ABSORPTION INHIBITORS
- X. FIBRIC ACID DERIVATIVES
- Y. HMG-COA REDUCTASE INHIBITORS (STATINS)
- Z. NIACIN AGENTS
- AA. ANTIPSORIATIC AGENTS - TOPICAL VITAMIN D ANALOGS
- BB. TOPICAL ANALGESICS
- CC. ACNE AGENTS: TOPICAL, BENZOYL PEROXIDE, ANTIBIOTICS AND COMBINATION PRODUCTS
- DD. IMPETIGO AGENTS: TOPICAL
- EE. TOPICAL ANTIVIRALS

FF. TOPICAL SCABICIDES
 GG. IMMUNOMODULATORS: TOPICAL
 HH. TOPICAL RETINOIDS
 II. SEROTONIN-RECEPTOR ANTAGONISTS/COMBO
 JJ. H2 BLOCKERS
 KK. PROTON PUMP INHIBITORS (PPIS)
 LL. GASTROINTESTINAL ANTIINFLAMMATORY AGENTS
 MM. GASTROINTESTINAL ENZYMES
 NN. 5-ALPHA REDUCTASE INHIBITORS
 OO. ALPHA-BLOCKERS
 PP. BLADDER ANTISPASMODICS
 QQ. ANTICOAGULANTS – INJECTABLE
 RR. COLONY STIMULATING FACTORS
 SS. PLATELET INHIBITORS
 TT. ALPHA-GLUCOSIDASE INHIBITORS/AMYLIN ANALOGS/MISC.
 UU. BIGUANIDES
 VV. DIPEPTIDYL PEPTIDASE-4 INHIBITORS
 WW. MEGLITINIDES
 XX. SULFONYLUREAS
 YY. THIAZOLIDINEDIONES
 ZZ. GROWTH HORMONE MODIFIERS
 AAA. PROGESTINS FOR CACHEXIA
 BBB. ANTIGOUT AGENTS
 CCC. BISPHOSPHONATES
 DDD. NASAL CALCITONINS
 EEE. RESTLESS LEG SYNDROME AGENTS
 FFF. SKELETAL MUSCLE RELAXANTS
 GGG. ALZHEIMERS AGENTS
 HHH. BARBITURATES
 III. BENZODIAZEPINES
 JJJ. HYDANTOINS
 KKK. NON-ERGOT DOPAMINE AGONISTS
 LLL. CARBONIC ANHYDRASE INHIBITORS/BETA-BLOCKERS
 MMM. OPHTHALMIC PROSTAGLANDINS
 NNN. OPHTHALMIC ANTIHISTAMINES
 OOO. OPHTHALMIC MACROLIDES
 PPP. OPHTHALMIC QUINOLONES
 QQQ. OPHTHALMIC CORTICOSTEROIDS
 RRR. OPHTHALMIC NONSTEROIDAL ANTIINFLAMMATORY DRUGS (NSAIDS)
 SSS. OTIC QUINOLONES
 TTT. ANTIDEPRESSANTS – OTHER
 UUU. SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS)

VVV. ATYPICAL ANTIPSYCHOTICS
WWW. NASAL ANTIHISTAMINES
XXX. LEUKOTRIENE RECEPTOR ANTAGONISTS
YYY. NASAL CORTICOSTEROIDS
ZZZ. PHOSPHODIESTERASE TYPE 4 INHIBITORS
AAAA. RESPIRATORY ANTIMUSCARINICS
BBBB. LONG-ACTING RESPIRATORY BETA-AGONIST
CCCC. SHORT-ACTING RESPIRATORY BETA-AGONIST
DDDD. RESPIRATORY CORTICOSTEROID/LONG-ACTING BETA-AGONIST COMBINATIONS
EEEE. ANTIDOTES - OPIATE ANTAGONISTS

VIII. REPORT BY CATAMARAN ON NEW DRUGS TO MARKET, NEW GENERIC DRUGS TO MARKET, AND NEW LINE EXTENSIONS

IX. REVIEW OF NEXT MEETING LOCATION, DATE, AND TIME

A. December 3, 2015

X. PUBLIC COMMENT

XI. ADJOURNMENT

This notice and agenda has been posted on or before 9:00 a.m. on the third working day before the meeting at the following locations:

Notice of this meeting will be available on or after the posting date of this Agenda at the DHCFP Web site (<http://dhcfp.nv.gov/>)

Posting of the Agenda will be at the Nevada Medicaid Central offices in Carson City and Las Vegas; Nevada State Library; Carson City Library; Churchill County Library; Las Vegas Library; Douglas County Library; Elko County Library; Lincoln County Library; Lyon County Library; Mineral County Library; Tonopah Public Library; Pershing County Library; Goldfield Public Library; Eureka Branch Library; Humboldt County Library; Lander County Library; Storey County Library; Washoe County Library; and White Pine County Library and may be reviewed during normal business hours.

If requested in writing, a copy of the action items will be mailed to you or they may be reviewed Monday through Friday from 9:00 a.m. until 5:00 p.m., or at the meeting. Please call at least one day ahead for an appointment for document review. Written comments on the proposed changes may be sent to the DHCFP, 1100 E. William Street, Suite 102, Carson City, NV 89701.

All persons that have requested in writing to receive the Open Meeting Agenda have been duly notified by mail or e-mail.

Anyone presenting documents for consideration during the public comment portion of the meeting must provide sufficient copies for each member of the committee and the official record. Copies are to be distributed at the time of the meeting and should be provided at both meeting locations; DHCFP or its contractor will not distribute public comment information or materials prior to the public meeting.